AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) Director Ecor1 Capital, Llc purchased 138,093 shares of the firm’s stock in a transaction that occurred on Wednesday, November 18th. The shares were bought at an average price of $46.54 per share, with a total value of $6,426,848.22. Following the completion of the acquisition, the director owned 8,254,674 shares of the company’s stock, valued at $384,172,527.96. This trade represents a 1.70% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Ecor1 Capital, Llc also recently made the following trade(s):
- On Tuesday, November 17th, Ecor1 Capital, Llc purchased 152,367 shares of AnaptysBio stock. The shares were purchased at an average cost of $45.66 per share, with a total value of $6,957,077.22.
- On Monday, November 16th, Ecor1 Capital, Llc bought 84,120 shares of AnaptysBio stock. The shares were bought at an average price of $45.66 per share, for a total transaction of $3,840,919.20.
AnaptysBio Price Performance
NASDAQ:ANAB opened at $47.40 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 8.40 and a quick ratio of 8.40. The firm has a fifty day simple moving average of $49.02 and a 200 day simple moving average of $56.26. AnaptysBio, Inc. has a 1-year low of $22.07 and a 1-year high of $72.36.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the stock. Ruffer LLP bought a new stake in AnaptysBio during the third quarter worth about $5,356,000. Virtu Financial LLC bought a new stake in shares of AnaptysBio in the 3rd quarter valued at about $255,000. Goldman Sachs Group Inc. increased its stake in shares of AnaptysBio by 45.6% during the third quarter. Goldman Sachs Group Inc. now owns 850,343 shares of the biotechnology company’s stock worth $42,738,000 after purchasing an additional 266,273 shares during the period. Entropy Technologies LP bought a new stake in shares of AnaptysBio in the third quarter valued at approximately $468,000. Finally, HighVista Strategies LLC bought a new position in AnaptysBio in the 3rd quarter valued at about $598,000.
Analyst Ratings Changes
Several equities research analysts have issued reports on the stock. Wall Street Zen cut shares of AnaptysBio from a “buy” rating to a “hold” rating in a research report on Sunday, October 4th. Wolfe Research reissued an “outperform” rating and set a $78.00 price objective on shares of AnaptysBio in a research report on Monday, August 31st. TD Cowen dropped their target price on shares of AnaptysBio from $75.00 to $70.00 and set a “buy” rating on the stock in a research report on Tuesday, August 25th. Weiss Ratings reiterated a “sell (e+)” rating on shares of AnaptysBio in a research report on Wednesday, November 4th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of AnaptysBio in a research report on Tuesday, September 22nd. Twelve equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, AnaptysBio presently has a consensus rating of “Moderate Buy” and an average target price of $75.67.
View Our Latest Research Report on ANAB
About AnaptysBio
AnaptysBio is a biotechnology company focused on developing antibody-based treatments for inflammatory and autoimmune diseases. Its research programs target immune pathways that may be involved in conditions with significant unmet medical needs. The company’s pipeline has included rosnilimab, an investigational antibody designed to activate the PD-1 pathway, and ANB032, an investigational antibody targeting BTLA. AnaptysBio has also developed imsidolimab, an antibody targeting the IL-36 receptor; global rights to that program were licensed to Vanda Pharmaceuticals.
Featured Stories
- Five stocks we like better than AnaptysBio
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.
